Organization
Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
3 abstracts
Abstract
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy, Department of Pulmonology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands, Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France,
Abstract
Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).Org: Norwegian University of Science and Technology (NTNU), Department of Thoracic Medicine, Haukeland University Hospital, Department of Oncology, Oslo University Hospital, Oslo, Oslo, Norway, Stavanger University Hospital, Department of Oncology, Odense University Hospital,
Abstract
Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).Org: University of Bergen, Norwegian University of Science and Technology (NTNU), Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, Sykehuset Innlandet,